Exploring Big Data in Hematological Malignancies: Challenges and Opportunities

被引：1
|
作者：
Westin, Gustavo F. [1 ]
Dias, Ajoy L. [1 ]
Go, Ronald S. [1 ]
机构：
[1] Mayo Clin, Div Hematol, 200 First St SW, Rochester, MN 55905 USA
来源：
CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2016年 / 11卷 / 04期
关键词：
Acute myeloid leukemia; Hodgkin lymphoma; Diffuse large B cell lymphoma; Multiple myeloma; Amyloidosis; Hematopoietic stem cell transplantation; CHRONIC LYMPHOCYTIC-LEUKEMIA; STEM-CELL TRANSPLANTATION; CHEMOTHERAPY PLUS RITUXIMAB; STAGE HODGKINS LYMPHOMA; ACUTE MYELOID-LEUKEMIA; HIGH-DOSE MELPHALAN; HEALTH-CARE-SYSTEM; MULTIPLE-MYELOMA; ELDERLY-PATIENTS; UNDETERMINED SIGNIFICANCE;
D O I：
10.1007/s11899-016-0331-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Secondary analysis of large datasets has become a useful alternative to address research questions outside the reach of clinical trials. It is increasingly utilized in hematology and oncology. In this review, we provided an overview of some examples of commonly used large datasets in the USA and described common research themes that can be pursued using such a methodology. We selected a sample of 14 articles on adult hematologic malignancies published in 2015 and highlighted their contributions as well as limitations.
引用
收藏
页码：271 / 279
页数：9
相关论文
共 50 条
  • [21] Checkpoint inhibitors in hematological malignancies
    Ok, Chi Young
    Young, Ken H.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [22] Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies
    Na, Il-Kang
    Buckland, Matthew
    Agostini, Carlo
    Edgar, John David M.
    Friman, Vanda
    Michallet, Mauricette
    Sanchez-Ramon, Silvia
    Scheibenbogen, Carmen
    Quinti, Isabella
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (06) : 447 - 456
  • [23] Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies
    Fulda, S.
    LEUKEMIA, 2012, 26 (06) : 1155 - 1165
  • [24] Epialleles and epiallelic heterogeneity in hematological malignancies
    Benetatos, Leonidas
    Benetatou, Agapi
    Vartholomatos, Georgios
    MEDICAL ONCOLOGY, 2022, 39 (10)
  • [25] Polymeric nanomedicines targeting hematological malignancies
    Gu, Wenxing
    Qu, Ruobing
    Meng, Fenghua
    Cornelissen, Jeroen J. L. M.
    Zhong, Zhiyuan
    JOURNAL OF CONTROLLED RELEASE, 2021, 337 : 571 - 588
  • [26] ENMD-2076 for hematological malignancies
    How, Jonathan
    Yee, Karen
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (05) : 717 - 732
  • [27] Recent Progress of CircRNAs in Hematological Malignancies
    Cui, Ya-Bin
    Wang, Li-Jie
    Xu, Jin-Hui
    Nan, Hui-Jie
    Yang, Pei-Yao
    Niu, Jun-Wei
    Shi, Ming-Yue
    Bai, Yan-Liang
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2024, 21 (13): : 2544 - 2561
  • [28] The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
    Zhao, Zijun
    Chen, Yu
    Francisco, Ngiambudulu M.
    Zhang, Yuanqing
    Wu, Minhao
    ACTA PHARMACEUTICA SINICA B, 2018, 8 (04) : 539 - 551
  • [29] From food to clinical medicine - nutraceuticals as clinical therapeutics for hematological malignancies
    Angka, L.
    Spagnuolo, P. A.
    CURRENT OPINION IN FOOD SCIENCE, 2015, 4 : 7 - 12
  • [30] MicroRNAs in hematological malignancies
    Lawrie, Charles H.
    BLOOD REVIEWS, 2013, 27 (03) : 143 - 154
12345